EichorEICHOR
Study identifier: NCT04493632 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: RecruitingOSPREY

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Condition: Pancreatic Neoplasm · Digestive System Neoplasm · Neoplasms by Site  ·  Sponsor: OncoSil Medical Limited

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNoCheck eligibility criteria ↓
Where9 locations · 2 countries

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry. The Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.

This description comes directly from the study's public registry record.

Talk to the study team

Tom Maher  ·  +44 750 4658585  ·  tom.maher@oncosil.com

Nicole G Gaddi, B.Sc Nursing  ·  + 61 (0)428 946 588  ·  nicole.gaddi@oncosil.com

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: 1. Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC). 2. Patients who undergo OncoSil™ implantation at an eligible treatment facility. 3. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPREY Patient Registry. 4. Pancreatic target tumour recommended size of \<7 cm (longest diameter) and \<110 cc volume. 5. A clinically acceptable ECOG performance status. 6. Patients ≥ 18 years of age at screening. 7. To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to the approved prescribing schedule) post Registry enrolment. 8. Adequate biochemical tests, coagulation profile, haematological, renal, and hepatic function as determined by the Treating Physician. Exclusion Criteria: 1. Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREY Patient Registry. 2. Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored). 3. Evidence of distant metastases based on review of baseline CT scan. 4. More than one primary lesion. 5. In the opinion of the Treating Physician, EUS-directed implantation posing undue patient risk. This includes: * where previous EUS-FNA was considered technically too difficult to perform; * imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas; * presence (or significant risk) of varices near to the target tumour. 6. Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment). 7. In the setting of recent, clinically significant pancreatitis, implantation is not recommended. 8. Pregnant or intending to commence a pregnancy within 12-months of the intended date of implantation or breastfeeding. 9. Patients who have a known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (9)

Complejo Hospitalario Universitario Insular Materno-InfantilLas Palmas de Gran Canaria, SpainRecruiting
Hospital Universitario Ramón y CajalMadrid, SpainRecruiting
Hospital Universitario de FuenlabradaMadrid, SpainRecruiting
Hospital Universitario Doce De OctobreMadrid, SpainNot Yet Recruiting
Hospital Universitario La PazMadrid, SpainNot Yet Recruiting
Clinica Universidad De NavarraPamplona, SpainRecruiting
Hospital Clinico Universitario De ValladolidValladolid, SpainRecruiting
Hammersmith HospitalLondon, United KingdomNot Yet Recruiting
The London ClinicLondon, United KingdomNot Yet Recruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Las Palmas de Gran CanariaMadridPamplonaValladolid

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →